Teva Pharmaceutical under investigation for securities violations

Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Teva Pharmaceutical Industries Limited (NYSE: TEVA) (“TEVA” or the “Company”) for violations of federal securities laws.

On August 18, 2020, Reuters reported that “The U.S. government sued Teva Pharmaceutical Industries Ltd on Tuesday, accusing the drugmaker of causing the submission of false claims to Medicare as a result of kickbacks it paid for its multiple sclerosis drug Copaxone.”

Following this news, shares of Teva were down over 13% in early morning trading on August 18, 2020.

If you have information that could assist in this investigation, including past employees and others, or if you are a Teva shareholder and are interested in learning more about the investigation, please contact Jim Baker (jimb@johnsonfistel.com) by email or phone at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [click here to join this action]. There is no cost or obligation to you.

Share: